Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|July 23, 2020
LabVantage COVID-19 LIMS Solution Launched for Workplace Health and Safety
Author(s)Pharmaceutical Technology Editors
An LIMS system enables a COVID-19 testing center for employees at their workplace.
Advertisement
LabVantage Solutions, a laboratory information management system provider based in Somerset, NJ, has a COVID-19 laboratory information management system (LIMS) solution that can be used for companies to improve employee health and safety in the workplace.
According to July 22, 2020 press release, a global consumer packaged goods (CPG) company has utilized the LIMS solution to open an in-house COVID-19 testing center where employees can be tested for the SARS-CoV-2 virus that causes COVID-19. Employees showing signs and symptoms of the virus, or those who request a test, can be scheduled for an appointment using the system.
LabVantage’s COVID-19 LIMS solution lets health professionals schedule, collect samples, test, track, and report results, the press release said. It comes preconfigured to prepare sample requests, label sample specimens, and track patient and sample data while following privacy and security protocols, and it handles results and reporting in a single interface.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement